NOVOLOG INNOLET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLOG INNOLET (NOVOLOG INNOLET).
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity, which leads to glucose transporter translocation and metabolic effects.
| Metabolism | Insulin aspart is metabolized primarily by proteolytic enzymes, likely insulin-degrading enzyme (IDE). The exact metabolic pathways are not fully characterized. |
| Excretion | Renal: approximately 30% of total clearance as unchanged drug; hepatobiliary/fecal: minor (less than 1%) |
| Half-life | Terminal half-life: 81 minutes (range 70–90 minutes) for subcutaneous administration; reflects absorption-rate limited elimination |
| Protein binding | >98% bound to albumin; minimal binding to globulins |
| Volume of Distribution | 0.25 L/kg; indicates distribution primarily into extracellular fluid |
| Bioavailability | Subcutaneous: 60–80% (injection site dependent; no intravenous formulation) |
| Onset of Action | Subcutaneous: 10–20 minutes (rapid-acting analog) |
| Duration of Action | Subcutaneous: 3–5 hours; dose-dependent, shorter at lower doses |
Subcutaneous injection, 0.5-1.0 unit/kg/day in divided doses, with meals.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-60 mL/min: initiate with caution and reduce dose by 25%; For GFR <30 mL/min: reduce dose by 50% and monitor glucose closely. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% and monitor glucose closely. |
| Pediatric use | Weight-based dosing: 0.5-1.0 unit/kg/day subcutaneously in divided doses with meals; for children <2 years, not recommended. |
| Geriatric use | Initiate with dose reduction of 25-50% due to increased risk of hypoglycemia; titrate slowly based on glucose response. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVOLOG INNOLET (NOVOLOG INNOLET).
| Breastfeeding | Insulin aspart is excreted into breast milk in negligible amounts (M/P ratio not established). It is considered compatible with breastfeeding. Maternal insulin requirements may decrease postpartum. |
| Teratogenic Risk | Insulin aspart (NOVOLOG) is not teratogenic in human studies. Poorly controlled diabetes increases risk of congenital anomalies, macrosomia, and neonatal hypoglycemia. First trimester: no fetal malformations attributed to insulin aspart. Second/third trimester: risk of fetal hyperinsulinism and macrosomia if maternal hyperglycemia occurs. |
■ FDA Black Box Warning
Changes in insulin strength, manufacturer, type, or method of administration should be done under close medical supervision as changes may result in the need for a change in dosage.
| Serious Effects |
["Hypersensitivity to insulin aspart or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia is the most common adverse reaction; may be life-threatening if severe.","Never share a Novolog Innolet pen between patients, even if the needle is changed.","Monitor glucose closely during illness, stress, or changes in diet/exercise.","Risk of hypokalemia; monitor potassium levels if at risk.","Accidental mix-ups between insulin products can occur; verify label before administration.","Adjust dose in patients with renal or hepatic impairment."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose profiles frequently (preprandial and postprandial). Assess HbA1c every trimester. Fetal surveillance: ultrasound for growth and anatomy, nonstress test or biophysical profile in third trimester. Monitor for maternal hypoglycemia. |
| Fertility Effects | No direct adverse effects on fertility. Uncontrolled diabetes can impair fertility; improved glycemic control may enhance reproductive outcomes. |